rabeprazole has been researched along with Colorectal Neoplasms in 4 studies
Rabeprazole: A 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
Colorectal Neoplasms: Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We enrolled patients administered adjuvant capecitabine plus oxaliplatin (CapeOX) for postoperative colorectal cancer (CRC) patients and metastatic CRC patients receiving CapeOX with/without bevacizumab." | 3.91 | Rabeprazole intake does not affect systemic exposure to capecitabine and its metabolites, 5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluorouridine, and 5-fluorouracil. ( Fujita, KI; Ishida, H; Ishikawa, F; Kubota, Y; Ohkuma, R; Sasaki, Y; Sekido, M; Shibanuma, M; Takahashi, T; Tsunoda, T, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Matsuoka, H | 1 |
| Ando, K | 1 |
| Swayze, EJ | 1 |
| Unan, EC | 1 |
| Mathew, J | 1 |
| Hu, Q | 1 |
| Tsuda, Y | 1 |
| Nakashima, Y | 1 |
| Saeki, H | 1 |
| Oki, E | 1 |
| Bharti, AK | 1 |
| Mori, M | 1 |
| Sekido, M | 1 |
| Fujita, KI | 1 |
| Kubota, Y | 1 |
| Ishida, H | 1 |
| Takahashi, T | 1 |
| Ohkuma, R | 1 |
| Tsunoda, T | 1 |
| Ishikawa, F | 1 |
| Shibanuma, M | 1 |
| Sasaki, Y | 1 |
| Falcone, R | 1 |
| Roberto, M | 1 |
| D'Antonio, C | 1 |
| Romiti, A | 1 |
| Milano, A | 1 |
| Onesti, CE | 1 |
| Marchetti, P | 1 |
| Fais, S | 1 |
| Takeshima, F | 1 |
| Senoo, T | 1 |
| Matsushima, K | 1 |
| Akazawa, Y | 1 |
| Yamaguchi, N | 1 |
| Shiozawa, K | 1 |
| Ohnita, K | 1 |
| Ichikawa, T | 1 |
| Isomoto, H | 1 |
| Nakao, K | 1 |
4 other studies available for rabeprazole and Colorectal Neoplasms
| Article | Year |
|---|---|
CTDSP1 inhibitor rabeprazole regulates DNA-PKcs dependent topoisomerase I degradation and irinotecan drug resistance in colorectal cancer.
Topics: Cell Line, Tumor; Colonic Neoplasms; Colorectal Neoplasms; DNA; DNA Topoisomerases, Type I; DNA-Acti | 2020 |
Rabeprazole intake does not affect systemic exposure to capecitabine and its metabolites, 5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluorouridine, and 5-fluorouracil.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Area Under Cu | 2019 |
High-doses of proton pump inhibitors in refractory gastro-intestinal cancer: A case series and the state of art.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Colorectal Neoplasms; Humans; Male; Neoplasm Metastasis | 2016 |
Successful management of cap polyposis with eradication of Helicobacter pylori relapsing 15 years after remission on steroid therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2012 |